Pfizer's RSV Vaccine Abrysvo Shows Positive Results in Study

Aug 12, 2024, 10:48 AM

Pfizer announced that its respiratory syncytial virus (RSV) vaccine, Abrysvo, has shown positive results in a late-stage study involving immunocompromised adults. The study demonstrated that Abrysvo generated a strong immune response across four groups of adults. This development marks a significant step for Pfizer as it seeks to expand its vaccine offerings and address the needs of vulnerable populations.